We are live on ! Find out more
ITRM

Iterum Therapeutics
ITRM

Delisted

ITRM was delisted on the 31st of March, 2026.

Back to rankings

16 hedge funds and large institutions have $762K invested in Iterum Therapeutics in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

314% more capital invested

Capital invested by funds: $184K → $762K (+$578K)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

7% more funds holding

Funds holding: 15 → 16 (+1)

1.14% more ownership

Funds ownership: 1.74% → 2.88% (+1.1%)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$12.4K
2
UBS Group
UBS Group
Switzerland
+$6.13K
3
Renaissance Technologies
Renaissance Technologies
New York
+$3.72K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$37.3K
2
Citadel Advisors
Citadel Advisors
Florida
-$16.2K
3
Morgan Stanley
Morgan Stanley
New York
-$10.5K
4
TRCT
Tower Research Capital (TRC)
New York
-$18
5
Osaic Holdings
Osaic Holdings
Arizona
-$15

ITRM Hedge Fund Activity: Q4 2023 in Review

16 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q4 2023, worth a combined $762K — up 314% from $184K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ITRM positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.

The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $12.4K. The largest seller was Susquehanna International Group, cutting an estimated $37.3K.

  • 16 institutional investors held Iterum Therapeutics (ITRM) as of Q4 2023, up from 15 in Q3 2023.
  • Funds reported $762K of Iterum Therapeutics stock for Q4 2023, up 314% quarter-over-quarter.
  • 3 funds opened new Iterum Therapeutics positions in Q4 2023 and 2 closed out, a net change of +1 holder.
  • The largest Iterum Therapeutics buyer in Q4 2023 was Royal Bank of Canada, an estimated $12.4K added.
  • The largest Iterum Therapeutics seller in Q4 2023 was Susquehanna International Group, an estimated $37.3K sold.

Based on aggregated 13F filings for Q4 2023.